Policy / Pricing Joint MHRA/NICE pathway ‘benefits industry over patients’ PharmaphorumLSE pharma policy expert contends the MHRA/NICE aligned pathway is weighted towards industry, and calls for an assessment of its impact on the NHS.Read full story pharminent May 14, 2026 (Last updated: May 16, 2026) Pharmaphorum LSE pharma policy expert contends the MHRA/NICE aligned pathway is weighted towards industry, and calls for an assessment of its impact on the NHS. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA’s leadership void leaves biotech with renewed ‘uncertainty’Next: Pfizer receives EC approval for Hympavzi to treat haemophilia Related Stories Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026 Policy / Pricing UK commits to pharma IP protection in Swiss trade deal pharminent July 16, 2026 Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026
